touchONCOLOGY joins Dr Alison Birtle (Consultant Oncologist and Honorary Senior Lecturer, Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK) to discuss the updated primary and secondary analysis of the POUT trial in upper tract urothelial cancer (ClinicalTrials.gov Identifier: NCT01993979). The abstract “Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC)” (Abstract 455) was presented at the 2021 Genitourinary Cancers Symposium, 11–13 February 2021.
Questions:
- Could you give us a brief overview of upper tract urothelial carcinoma, its prognosis and the unmet needs in its treatment? (0:05)
- What did the POUT trial teach us about the clinical utility of adjuvant chemotherapy in upper tract urothelial cancer? (2:13)
- You have already talked about the updated primary and secondary endpoints, could you also continue to update us on the other secondary endpoints? (6:50)
- How will these findings impact clinical practice? (9:48)
Disclosure: Dr Alison Birtle has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2021 Genitourinary Cancers Symposium (Virtual), 11–13 February 2021.
Reference
Birtle AJ, Chester JD, Jones R, et al. Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J Clin Oncol. 2021;36(Suppl. 6):407.
